Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal 5FU+Oxaliplatin in Colorectal Cancer With Peritoneal Metastasis
NCT06269978Phase 1Active, not recruiting
- Start
- Dec 2024
- Primary completion
- Sep 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxaliplatin and fluorouracil in colorectal cancer (CRC). Primary endpoints: Maximum tolerated dose up to 1 year, Incidence of adverse events and 4 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
oxaliplatinfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06269978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06269978.